Frankfurt - Delayed Quote • EUR
Evolus, Inc. (EVL.F)
As of 8:16 AM GMT+2. Market Open.
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. David Moatazedi | President, CEO & Director | 1.19M | -- | 1978 |
Ms. Sandra Beaver | Chief Financial Officer | 347.91k | -- | 1978 |
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. | Chief Medical Officer and Head of Research & Development | 637.47k | -- | 1962 |
Mr. Nareg Sagherian | Head of Global Investor Relations & Corporate Communications | -- | -- | -- |
Mr. Jeffrey J. Plumer | General Counsel | -- | -- | -- |
Mr. Kurt Knab | Vice President of Sales | -- | -- | -- |
Ms. Tomoko Yamagishi-Dressler | Chief Marketing Officer | -- | -- | -- |
Ms. Jessica Novak | Senior Vice President of Human Resources | -- | -- | -- |
Evolus, Inc.
520 Newport Center Drive
Suite 1200
Newport Beach, CA 92660
United States
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 273
Description
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Corporate Governance
Evolus, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
Recent Events Information Not Available
Upcoming Events
May 07, 2024
Evolus, Inc. Earnings Call